The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Summer 2022 RFP: The Edmond J. Safra Movement Disorders Research Career Development Award, 2022Tracking Eye Movements and Pupil Responses as a Diagnostic and Prognostic Biomarker in Parkinsonian Disorders
Study Rationale: We do not currently have accurate tests to diagnose Parkinson’s disease (PD) and the conditions which mimic it (atypical parkinsonism) at a very early stage. Similarly, we do not have...
-
Fall 2020 RFA: Therapeutic Pipeline Program-Pre-Clinical, 2022Assessing a Novel Strategy for Noninvasive Stimulation of Dopamine-producing Neurons in Preclinical Models of Parkinson’s Disease
Rationale: Parkinson’s disease (PD) is caused by the progressive degeneration of the dopamine-producing neurons responsible for initiating and refining voluntary movements. Treatments based on drugs...
-
Spring 2022 RFA: Target Advancement Program - Target Validation, 2022Production of Preclinical Model of REM Sleep Behavior Disorder Using Alpha-synuclein Fibrils
Study Rationale: REM sleep behavior disorder (RBD) is characterized by abnormal motor behaviors during the REM phase of sleep and is highly predictive of Parkinson’s disease (PD). A brain region...
-
Spring 2022 RFA: Target Advancement Program - Target Validation, 2022Examining the Action of Potassium Channels and the Inflammasome in a Signaling Axis That Can Serve as a Pharmacological Target Against Parkinson’s Disease
Study Rationale: Both voltage-gated potassium channels and inflammatory signaling are known to be involved in Parkinson’s disease (PD). Each of these signaling systems contributes to the brain...
-
Therapeutic Pipeline Program, 2022Developing Selective Ion Channel Blockers that Reduce Neuroinflammation in Parkinson’s Disease
Study Rationale: We are developing novel therapeutics to reduce brain inflammation and enhance the survival and function of brain cells in Parkinson’s disease (PD). Studies over the past decade have...
-
Spring 2022 RFA: Target Advancement Program - Tool Generation, 2022Design and testing of a FRET sensor for Parkin activity
Study Rationale: Parkin is a protein that is encoded by a gene which is frequently mutated in Parkinson’s disease. It is known to be involved in getting rid of damaged mitochondria in cells and this...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.